ADAD“The aducanumab results presented today are truly exciting and represent a major breakthrough in the treatment of Alzheimer’s disease,” Turner said in an email. If approved, the drug would become the first to treat the underlying pathology of the dementia-causing disease. ADADThe drug appears to allow people in the early stages of Alzheimer’s disease to continue independently going about their daily business longer than people who didn’t take it. There are drugs on the market that alleviate some of the symptoms of Alzheimer’s disease, such as memantine and donepezil, which is commonly sold as Aricept and treats symptoms of memory loss. “It’s a plausible explanation for the positive study and the negative study,” said Ronald Petersen, who directs the Mayo Clinic Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging.

Source: Washington Post December 05, 2019 23:37 UTC